lobbying_activities: 3389316

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3389316 d20a6877-cc48-4b78-b729-ee883fd655f3 Q2 FAEGRE DRINKER BIDDLE & REATH LLP 12631 TEVA PHARMACEUTICALS USA, INC. 2025 second_quarter CPT Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-07-17T15:04:06-04:00